Additional Files

Fairman, C. M., & Christensen, J. F. (2021). Targeted Exercise Training for Cancer Patients: Moving beyond Generic Exercise Guidelines in Clinical Oncology. Translational Medicine and Exercise Prescription, 1(1), 43–52. https://doi.org/10.53941/tmep.v1i1.35

Targeted Exercise Training for Cancer Patients: Moving beyond Generic Exercise Guidelines in Clinical Oncology

Ciaran M Fairman1 and Jesper F Christensen()2,3 

1Department of Exercise Science, University of South Carolina, USA

2Center for Physical Activity Research, Rigshospitalet, Copenhagen, Denmark

3Department of Sports Science and Clinical Biomechanics, Faculty of Health Sciences, University of Southern Denmark, Denmark

© The Authors


 

Abstract

The field of exercise oncology has rapidly evolved over the past 30 years. Initial investigations of safety and feasibility have progressed towards efficacy and effectiveness trials with a variety of health-related outcomes in mind. More recently, it has been recognized that interventions aimed at modifying physical activity behavior (i.e. behavioral interventions to increase participation in un/structured physical activity) are distinctly different from those aiming to target a clinically relevant outcome (using a specific exercise prescription). There is a strong rationale for the latter, where cancer/treatment toxicities can result in musculoskeletal, cardiopulmonary, and/or hematological declines with important prognostic implications. Treatment intolerance, unfavorable tumor response and heightened risk of mortality are all consequences of leaving these impairments unaddressed. Importantly, the control/reversal of the decline in these systems is more likely to occur through a targeted exercise prescription, specifically designed to target the impairment, rather than interventions trying to change behavior. This requires careful consideration in the study design in exercise oncology in relation to the selection of clinically relevant outcomes, decisions on methods of assessments and ensuring the exercise is targeted to the outcome.

    The objective of this review is to 1) conceptualize and provide a clinical rationale for targeted exercise interventions in exercise oncology, and 2) provide a framework for consideration in the design and execution in targeted exercise interventions in oncology. We hope that this framework can encourage research into targeted exercise interventions in oncology and that our framework can be used to inform the design of future trials.

exercise oncology targeted exercise cancer-related outcomes exercise prescription

References

  1. Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al. Exercise guidelines for cancer survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc 2019, 51(11): 2375-90. https://doi.org/10.1249/MSS.0000000000002116
  2. Schmitz KH,Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010, 42(7): 1409-26. https://doi.org/10.1249/MSS.0b013e3181e0c112
  3. Antunes JMM, Ferreira RMP, Moreira-Goncalves D. Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol Med 2018, 24(8): 709-27. https://doi.org/10.1016/j.molmed.2018.06.002.
  4. Brown JC, Cespedes Feliciano EM, Caan BJ. The evolution of body composition in oncology-epidemiology, clinical trials, and the future of patient care: facts and numbers. J Cachexia, Sarcopenia Muscle 2018, 9(7): 1200-208. https://doi.org/10.1002/jcsm.12379
  5. Mercier J, Savard J, Bernard P. Exercise interventions to improve sleep in cancer patients: A systematic review and meta-analysis. Sleep Med Rev 2017, 36: 43-56. https://doi.org/10.1016/j.smrv.2016.11.001
  6. Brown JC,Huedo-Medina TB, Pescatello LS, Ryan SM, Pescatello SM, Moker E, et al. The efficacy of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis. PLoS ONE 2012, 7(1): e30955. https://doi.org/10.1371/journal.pone.0030955
  7. Hayes SC, Newton RU, Spence RR, Galvão DA. The exercise and sports science Australia position statement: exercise medicine in cancer management. J Sci Med Sport 2019, 22(11): 1175-99. https://doi.org/10.1016/j.jsams.2019.05.003
  8. Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol 2015, 7(4): 17-29. https://doi.org/10.4251/wjgo.v7.i4.17
  9. Aversa Z, Costelli P, Muscaritoli M. Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther Adv Med Oncol 2017, 9(5): 369-82. https://doi.org/10.1177/1758834017698643
  10. Fearon K,Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011, 12(5): 489-95. https://doi.org/10.1016/S1470-2045(10)70218-7
  11. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 2017, 31(1): 63-75. https://doi.org/10.1007/s10557-016-6711-0
  12. Kirkham AA, Lloyd MG, Claydon VE, Gelmon KA, McKenzie DC, Campbell KL. A longitudinal study of the association of clinical indices of cardiovascular autonomic function with breast cancer treatment and exercise training. Oncologist 2019, 24(2): 273-84. https://doi.org/10.1634/theoncologist.2018-0049
  13. Aahlin EK, Tranø G, Johns N, Horn A, Søreide JA, Fearon KC, et al. Health-related quality of life, cachexia and overall survival after major upper abdominal surgery: a prospective cohort study. Scand J Surg 2017, 106(1): 40-46. https://doi.org/10.1177/1457496916645962
  14. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009, 15(8): 2920-26. https://doi.org/10.1158/1078-0432.CCR-08-2242
  15. Owen PJ, Daly RM, Livingston PM, Fraser SF. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis 2017, 20(2): 137-45. https://doi.org/10.1038/pcan.2016.69
  16. Fairman CM, Zourdos MC, Helms ER, Focht BC. A scientific rationale to improve resistance training prescription in exercise oncology. Sports Med 2017, 47(8): 1457-65. https://doi.org/10.1007/s40279-017-0673-7
  17. Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Jessica Scott J, Jones LW, et al. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle 2015, 6(2): 115-24. https://doi.org/10.1002/jcsm.12042
  18. Christensen JF, Simonsen C, Hojman P. Exercise training in cancer control and treatment. Compr Physiol 2018, 9(1): 165-205. https://doi.org/10.1002/cphy.c180016
  19. Gilbert SM, Miller DC, Hollenbeck BK, Montie JE, Wei JT. Cancer survivorship: challenges and changing paradigms. J Urol 2008, 179(2): 431-38. https://doi.org/10.1016/j.juro.2007.09.029
  20. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA: A Cancer J Clin 2019, 69(5): 363-85. https://doi.org/10.3322/caac.21565
  21. Hurria A, Jones L, Muss HB. Cancer treatment as an accelerated aging process: assessment, biomarkers, and interventions. Am Soc Clin Oncol Educ Book 2016(36): e516-e22. https://doi.org/10.1200/EDBK_156160
  22. Moskowitz CS, Chou JF, Neglia JP, Partridge AH, Howell RM, Diller LR, et al. Mortality after breast cancer among survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2019, 37(24): 2120-30. https://doi.org/10.1200/JCO.18.02219
  23. Ng HS, Ng HS, Koczwara B, Roder D, Vitry A. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis 2018, 21(3): 403-10. https://doi.org/10.1038/s41391-018-0036-y
  24. Edgington A, Morgan MA. Looking beyond recurrence: comorbidities in cancer survivors. Clin J Oncol Nurs 2011, 15(1): E3-12. https://doi.org/10.1188/11.CJON.E3-E12
  25. Jones LW, Jones LW, Courneya KS, Mackey JR, Muss HB, Pituskin EN, Scott JM, et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol 2012, 30(20): 2530-37. https://doi.org/10.1200/JCO.2011.39.9014
  26. Scott JM, Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation 2018, 137(11): 1176-91. https://doi.org/10.1161/CIRCULATIONAHA.117.024671
  27. Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology 2016, 27(1): 6-13. https://doi.org/10.1097/EDE.0000000000000394
  28. Simões CM, Carmona MJC, Hajjar LA, Vincent JL, Landoni G, Belletti A, et al. Predictors of major complications after elective abdominal surgery in cancer patients. BMC Anesthesiol 2018, 18(1). https://doi.org/10.1186/s12871-018-0516-6
  29. Brunelli A, Belardinelli R, Refai M, Salati M, Socci L, Pompili C, et al. Peak oxygen consumption during cardiopulmonary exercise test improves risk stratification in candidates to major lung resection. Chest 2009, 135(5): 1260-67. https://doi.org/10.1378/chest.08-2059
  30. Simonsen C, de Heer P, Bjerre ED, Suetta C, Hojman P, Pedersen BK, et al. Sarcopenia and postoperative complication risk in gastrointestinal surgical oncology: a meta-analysis. Ann Surg 2018, 268(1): 58-69. https://doi.org/10.1097/SLA.0000000000002679
  31. Dajczman E, Kasymjanova G, Kreisman H, Swinton N, Pepe C, Small D. Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol 2008, 3(10): 1133-36. https://doi.org/10.1097/JTO.0b013e318186a272
  32. Scott JM, Stene G, Edvardsen E, Jones LW. Performance status in cancer: not broken, but time for an upgrade? J Clin Oncol 2020, 38(25): 2824-29. https://doi.org/10.1200/JCO.20.00721
  33. Schauer T, Hojman P, Gehl J, Christensen JF. Exercise training as prophylactic strategy in the management of neutropenia during chemotherapy. Br J Pharmacol 2020. https://doi.org/10.1111/bph.15141
  34. Courneya KS. Efficacy, effectiveness, and behavior change trials in exercise research. Int J Behav Nutr Phys Activity 2010, 7(1): 81. https://doi.org/10.1186/1479-5868-7-81
  35. Ekelund U, Steene-Johannessen J, Brown WJ, Fagerland MW, Owen N, Powell KE, et al. Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women. Lancet 2016, 388(10051): 1302-10. DOI:10.1016/S0140-6736(16)30370-1
  36. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd ed. Washington, DC; US. Department of Health and Human Services, 2019.
  37. Morville T,Sahl RE, Moritz T, Helge JW, Clemmensen C. Plasma metabolome profiling of resistance exercise and endurance exercise in humans. Cell Rep 2020, 33(13): 108554. https://doi.org/10.1016/j.celrep.2020.108554
  38. Khan MN, Khan AA. Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol 2008, 15(Suppl 1): S30-40. https://doi.org/10.3747/co.2008.174
  39. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 2006, 63(5): 419-30. https://doi.org/10.2146/ajhp050045.p1
  40. Benedetti MG, Furlini G, Zati A, Mauro GL. The effectiveness of physical exercise on bone density in osteoporotic patients. BioMed Res Int 2018, 2018: 1-10. https://doi.org/10.1155/2018/4840531
  41. Nystoriak MA, Bhatnagar A. Cardiovascular effects and benefits of exercise. Front Cardiovas Med 2018, 5. https://doi.org/10.3389/fcvm.2018.00135
  42. Aielli F, Ponzetti M, Rucci N. Bone metastasis pain, from the bench to the bedside. Int J Mol Sci 2019, 20(2): 280. https://doi.org/10.3390/ijms20020280
  43. Barreto R, mandili G, Witzmann FA, Novelli F, Zimmers TA, Bonetto A. Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front Physiol 2016, 7: 472. https://doi.org/10.3389/fphys.2016.00472
  44. Drake MT. Osteoporosis and cancer. Curr Osteoporos Rep 2013, 11(3): 163-70. https://doi.org/10.1007/s11914-013-0154-3
  45. Oh YL, Yoon MS, Suh DS, Kim A, Kim MJ, Lee JY, et al.Changes in bone density after cancer treatment in patients with cervical and endometrial cancer. J Cancer 2015, 6(1): 82-89. DOI:10.7150/jca.10679
  46. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008, 9(7): 629-35. https://doi.org/10.1016/S1470-2045(08)70153-0
  47. Weis J. Cancer-related fatigue: prevalence, assessment and treatment strategies. Expert Rev Pharmacoecon Outcomes Res 2011, 11(4): 441-46.
  48. Williams GR, Chen Y, Kenzik KM, McDonald A, Shachar SS, Klepin HD, et al. Assessment of sarcopenia measures, survival, and disability in older adults before and after diagnosis with cancer. JAMA Network Open 2020, 3(5): e204783. https://doi.org/10.1001/jamanetworkopen.2020.4783
  49. Baxi SS, Schwitzer E, Jones LW. A review of weight loss and sarcopenia in patients with head and neck cancer treated with chemoradiation. Cancers Head Neck 2016, 1(1). https://doi.org/10.1186/s41199-016-0010-0
  50. Capozzi LC, McNeely ML, Lau HY, Reimer RA, Giese-Davis J, Fung TS, et al. Patient-reported outcomes, body composition, and nutrition status in patients with head and neck cancer: Results from an exploratory randomized controlled exercise trial. Cancer 2016, 122(8): 1185-1200. https://doi.org/10.1002/cncr.29863
  51. Sheehan P, Denieffe S, Murphy NM, Harrison M. Exercise is more effective than health education in reducing fatigue in fatigued cancer survivors. Support Care Cancer 2020, 28(10): 4953-62. https://doi.org/10.1007/s00520-020-05328-w
  52. Zanolla L, Zardini P. Selection of endpoints for heart failure clinical trials. Europ J Heart Fail 2003, 5(6): 717-23. https://doi.org/10.1016/S1388-9842(03)00101-6
  53. Baker SG, Kramer BS. Surrogate endpoint analysis: an exercise in extrapolation. JNCI: J Nat Cancer Inst 2013, 105(5): 316-20. https://doi.org/10.1093/jnci/djs527
  54. Kaleth AS, Slaven JE, Ang DC. Determining the minimal clinically important difference for 6-minute walk distance in fibromyalgia. Am J Phys Med Rehabil 2016, 95(10): 738-45.
  55. Draak THP, de Greef BTA, Faber CG, Merkies ISJ, PeriNomS study group. The minimum clinically important difference: which direction to take. Europ J Neurol 2019, 26(6): 850-55. https://doi.org/10.1111/ene.13941
  56. Campbell KL, Neil SE, Winters-Stone KM. Review of exercise studies in breast cancer survivors: attention to principles of exercise training. Br J Sports Med 2012, 46(13): 909-16. https://doi.org/10.1136/bjsm.2010.082719
  57. Neil-Sztramko SE, Medysky ME,Campbell KL,Bland KA,Winters-Stone KM. Attention to the principles of exercise training in exercise studies on prostate cancer survivors: a systematic review. BMC Cancer 2019, 19(1):321. https://doi.org/10.1186/s12885-019-5520-9
  58. Neil-Sztramko SE, Winters-Stone KM, Bland KA, Campbell KL. Updated systematic review of exercise studies in breast cancer survivors: attention to the principles of exercise training. Br J Sports Med 2019, 53(8): 504-12. https://doi.org/10.1136/bjsports-2017-098389
  59. Winters-Stone KM, Neil SE, Campbell KL. Attention to principles of exercise training: a review of exercise studies for survivors of cancers other than breast. Br J Sports Med 2014, 48(12): 987-95. https://doi.org/10.1136/bjsports-2012-091732
  60. Helms ER, Kwan K, Sousa CA, Cronin JB,Storey AG, Zourdos MC. Methods for regulating and monitoring resistance Training. J Hum Kinet 2020, 74: 23-42. https://doi.org/10.2478/hukin-2020-0011
  61. Nilsen TS, Scott JM, Michalski M, Capaci C, Thomas S, Herndon JE 2nd, et al. Novel methods for reporting of exercise dose and adherence: an exploratory analysis. Med Sci Sports Exerc 2018, 50(6): 1134-41. https://doi.org/10.1249/MSS.0000000000001545
  62. Fairman CM, Nilsen TS, Newton RU, Taaffe DR, Spry N, Joseph D, et al. Reporting of resistance training dose, adherence, and tolerance in exercise oncology. Med Sci Sports Exerc 2020, 52(2): 315-22. https://doi.org/10.1249/MSS.0000000000002127
  63. Scott JM, Iyengar NM, Nilsen TS, Michalski M, Thomas SM, Herndon J 2nd, et al. Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial. Cancer 2018, 124(12): 2552-60. https://doi.org/10.1002/cncr.31368
  64. Jones LW. Precision oncology framework for investigation of exercise as treatment for cancer. J Clin Oncol 2015, 33(35): 4134-37. https://doi.org/10.1200/JCO.2015.62.7687